FDA approves Zydus’ Deflazacort oral suspension, 22.75 mg/mL
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends
This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Subscribe To Our Newsletter & Stay Updated